Skip to main content
. 2019 Oct 18;25(2):112–118. doi: 10.1634/theoncologist.2019-0356

Figure 3.

Figure 3

Functional validation of capicua transcriptional repressor (CIC) downregulation biological effect in multiple myeloma. (A): Cell viability assay measured with bioluminescence upon drug treatment with escalating doses of trametinib and dabrafenib in U266 human multiple myeloma cell line: scrambled versus CIC small interfering RNA (siRNA) transduced percentage of living cells are compared by ANOVA test. Experiments were conducted in three biological and technical replicates following manufacturer's instructions (CellTiter‐Glo Luminescent Cell Viability Assay; Promega, Madison, WI). (B): Scratch‐wound healing assay was performed as previously described 44, 45. Briefly, wound areas were analyzed with ImageJ Lab 1.51 software and quantified as percentage of total surface. (C): Western‐Blot analysis after CIC knockdown on U266 cells and corresponding densitometric quantification. (D): Dabrafenib and trametinib targets on RAS‐RAF pathway overview and CIC axis schematic interaction with the RAS‐RAF downstream signaling. ***p < .001; ****p < .0001.